Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Patricia Gogesch"'
Autor:
Steffi Krauter, Nicole Büscher, Eric Bräuchle, Samira Ortega Iannazzo, Inessa Penner, Nadine Krämer, Patricia Gogesch, Simone Thomas, Marina Kreutz, Mario Dejung, Anja Freiwald, Falk Butter, Zoe Waibler, Bodo Plachter
Publikováno v:
Vaccines, Vol 10, Iss 8, p 1326 (2022)
Human cytomegalovirus (HCMV) infection is associated with severe disease conditions either following congenital transmission of the virus or viral reactivation in immunosuppressed individuals. Consequently, the establishment of a protective vaccine i
Externí odkaz:
https://doaj.org/article/6b6f8b31f9634f6887338cdd87f2d9e4
Autor:
Marc A. Niles, Patricia Gogesch, Stefanie Kronhart, Samira Ortega Iannazzo, Georg Kochs, Zoe Waibler, Martina Anzaghe
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The exact role of innate immune cells upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their contribution to the formation of the corona virus-induced disease (COVID)-19 associated cytokine storm is not yet fully u
Externí odkaz:
https://doaj.org/article/f63d7aa6893349199e5e2e511cd772da
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 16, p 8947 (2021)
Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indicati
Externí odkaz:
https://doaj.org/article/7d60a0c09f1f411f85df0f2b24519f73
Autor:
Jens Weingarten, Melanie Laßek, Benjamin F. Mueller, Marion Rohmer, Dominic Baeumlisberger, Benedikt Beckert, Jens Ade, Patricia Gogesch, Amparo Acker-Palmer, Michael Karas, Walter Volknandt
Publikováno v:
Proteomes, Vol 3, Iss 2, Pp 74-88 (2015)
Neurotransmitter release as well as structural and functional dynamics at the presynaptic active zone (PAZ) comprising synaptic vesicles attached to the presynaptic plasma membrane are mediated and controlled by its proteinaceous components. Here we
Externí odkaz:
https://doaj.org/article/b8d1293d2bdc4cdf8fbe0dc83f95f3e0
Autor:
Patricia Gogesch, Inessa Penner, Steffi Krauter, Nicole Büscher, Leander Grode, Inci Aydin, Bodo Plachter
Publikováno v:
Vaccines, Vol 7, Iss 3, p 104 (2019)
Infections with the human cytomegalovirus (HCMV) are associated with severe clinical manifestations in children following prenatal transmission and after viral reactivation in immunosuppressed individuals. The development of an HCMV vaccine has long
Externí odkaz:
https://doaj.org/article/12fea483b3204ef4a694caee844f505a
Autor:
Alexander Mazein, Muhammad Shoaib, Miriam Alb, Christina Sakellariou, Charline Sommer, Katherina Sewald, Kristin Reiche, Patricia Gogesch, Luise A Roser, Samira Ortega Iannazzo, Sapna Sheth, Susanne Schiffmann, Zoe Waibler, Vanessa Neuhaus, Susann Dehmel, Venkata Satagopam, Reinhard Schneider, Marek Ostaszewski, Wei Gu
We address the need for modelling and predicting adverse outcomes in immunotoxicology to improve non-clinical assessments of immunomodulatory therapy safety and efficacy. The integrated approach includes, first, the adverse outcome pathway concept es
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a120503547f80780247e0a3025525e0a
https://doi.org/10.1101/2023.03.21.533620
https://doi.org/10.1101/2023.03.21.533620
Autor:
Aileen Ebenig, Samada Muraleedharan, Julia Kazmierski, Daniel Todt, Arne Auste, Martina Anzaghe, André Gömer, Dylan Postmus, Patricia Gogesch, Marc Niles, Roland Plesker, Csaba Miskey, Michelle Gellhorn Serra, Angele Breithaupt, Cindy Hörner, Carina Kruip, Rosina Ehmann, Zoltan Ivics, Zoe Waibler, Stephanie Pfaender, Emanuel Wyler, Markus Landthaler, Alexandra Kupke, Geraldine Nouailles, Christine Goffinet, Richard J.P. Brown, Michael D. Mühlebach
Vaccine-associated enhanced respiratory disease (VAERD) is a severe complication for some respiratory infections. To investigate the potential for VAERD induction in coronavirus disease 2019 (COVID-19), we evaluate two vaccine leads utilizing a sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27466db8ae8b4532e40612e5d44b512d
http://edoc.mdc-berlin.de/22013/7/22013suppl.zip
http://edoc.mdc-berlin.de/22013/7/22013suppl.zip
Autor:
Aileen, Ebenig, Samada, Muraleedharan, Julia, Kazmierski, Daniel, Todt, Arne, Auste, Martina, Anzaghe, André, Gömer, Dylan, Postmus, Patricia, Gogesch, Marc, Niles, Roland, Plesker, Csaba, Miskey, Michelle, Gellhorn Serra, Angele, Breithaupt, Cindy, Hörner, Carina, Kruip, Rosina, Ehmann, Zoltan, Ivics, Zoe, Waibler, Stephanie, Pfaender, Emanuel, Wyler, Markus, Landthaler, Alexandra, Kupke, Geraldine, Nouailles, Christine, Goffinet, Richard J P, Brown, Michael D, Mühlebach
Publikováno v:
Cell reports. 40(7)
Vaccine-associated enhanced respiratory disease (VAERD) is a severe complication for some respiratory infections. To investigate the potential for VAERD induction in coronavirus disease 2019 (COVID-19), we evaluate two vaccine leads utilizing a sever
Autor:
Aileen Ebenig, Samada Muraleedharan, Julia Kazmierski, Daniel Todt, Arne Auste, Martina Anzaghe, André Gömer, Dylan Postmus, Patricia Gogesch, Marc Niles, Roland Plesker, Csaba Miskey, Michelle Gellhorn Serra, Angele Breithaupt, Cindy Hörner, Carina Kruip, Rosina Ehmann, Zoltan Ivics, Zoe Waibler, Stephanie Pfaender, Emanuel Wyler, Markus Landthaler, Alexandra Kupke, Geraldine Nouailles, Christine Goffinet, Richard J.P. Brown, Michael D. Mühlebach
Since December 2019, the novel human coronavirus SARS-CoV-2 has spread globally, causing millions of deaths. Unprecedented efforts have enabled development and authorization of a range of vaccines, which reduce transmission rates and confer protectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0ee66773573f04284c10a648f85bc97
https://doi.org/10.1101/2021.12.28.474359
https://doi.org/10.1101/2021.12.28.474359
Publikováno v:
International Journal of Molecular Sciences
International journal of molecular sciences, 22(16):8947
International Journal of Molecular Sciences, Vol 22, Iss 8947, p 8947 (2021)
International journal of molecular sciences, 22(16):8947
International Journal of Molecular Sciences, Vol 22, Iss 8947, p 8947 (2021)
Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indicati